RadNet (RadNet) ROCE % : 4.12% (As of Dec. 2023)

View and export this data going back to 1997. Start your Free Trial

What is RadNet ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. RadNet's annualized ROCE % for the quarter that ended in Dec. 2023 was 4.12%.

RadNet ROCE % Historical Data

The historical data trend for RadNet's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RadNet ROCE % Chart

RadNet Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

7.10

3.33

7.01

5.14

4.90

RadNet Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															4.77	0.52	5.61	8.33	4.12

RadNet ROCE % Calculation

RadNet's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	103.293	/	( ( (2433.907 - 466.723)	+	(2690.473 - 437.452) )	/ 2 )
	=	103.293	/	( (1967.184	+	2253.021)	/ 2 )
	=	103.293	/	2110.1025
	=	4.90 %

RadNet's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	93.34	/	( ( (2688.025 - 407.077)	+	(2690.473 - 437.452) )	/ 2 )
	=	93.34	/	( ( 2280.948	+	2253.021 )	/ 2 )
	=	93.34	/	2266.9845
	=	4.12 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

RadNet (NAS:RDNT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

RadNet ROCE % Related Terms

Thank you for viewing the detailed overview of RadNet's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

RadNet (RadNet) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » RadNet Inc (NAS:RDNT) » Definitions » ROCE %

Comparable Companies

NEOG SHC GH NEO TWST MYGN VCYT OPK LAB FLGT TSE:2309 TMO DHR IQV IDXX XSWX:LONN A MTD ICLR ILMN

Traded in Other Exchanges

PQIA:Germany

Address

1510 Cotner Avenue, Los Angeles, CA, USA, 90025

Website

http://www.radnet.com

RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments; Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures, and Artificial Intelligence segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. The company derives a majority of its revenue from the Imaging center segment.

Executives

Michael N Murdock	officer: Executive Vice President	3600 JP MORGAN CHASE TOWER, 2200 ROSS AVENUE, DALLAS TX 752012776
Christine Nayoma Gordon	director	3081 PANAMA AVE., CARMICHAEL CA 95608
Gregory Sorensen	director, officer: EVP Chief Science Officer	C/O DFB HEALTHCARE ACQUISITIONS CORP, 780 THIRD AVENUE, NEW YORK NY 10017
Norman R Hames	director, officer: Vice President
Stephen M Forthuber	officer: Executive Vice President	3600 JP MORGAN CHASE TOWER, 2200 ROSS AVENUE, DALLAS TX 75201-2776
Ruth Louisa Villigerwilson	director, officer: Senior Vice President	3700 WALNUT AVENUE, LONG BEACH CA 90801
David L Swartz	director	1510 COTNER AVENUE, LOS ANGELES CA 90025
Gregory E. Spurlock	director	4116 E. NORTHRIDGE CIRCLE, MESA AZ 85215-9807
John V Crues	director	1510 COTNER AVE, LOS ANGELES CA 90025
Lawrence L Levitt	director	2934 1/2 BEVERLY GLEN CIRCLE #325, LOS ANGELES CA 90077
Ranjan Jayanathan	officer: Chief Information Officer	13388 HUNT RIDGE ROAD, ELLICOTT CITY MD 21042
Laura Pastre Jacobs	director	10154 BRIDLEVALE DRIVE, LOS ANGELES CA 90064
Karen B. Kaplan Survivor's Trust	other: Indirect owner	10776 WILSHIRE BLVD/, LOS ANGELES CA 90024-6447
David Jeffrey Katz	officer: EVP and General Counsel	1510 COTNER AVE, LOS ANGELES CA 90025
Sherman Michael L Md	director